TRANSDERMAL PATCHES OF VALSARTAN: FORMULATION AND EVALUATION
Bhawana Sethi, Anil Kumar Sahdev*
ABSTRACT
Transdermal drug delivery system has been seen a veritable explosion
in the past decades. In the present scenario, very few transdermal
patches are available. Matrix-diffusion type transdermal film of
valsartan was designed with various concentration of HPMC (k4M,
K15M, K100M). Valsartan is a nonpeptide angiotensin II AT1 receptor
antagonist and very well-tolerating hypertension by specifically
blocking the action of angiotensin-II on the angiotensin Type-1
receptor. The drug has 23% bioavailability with biological half life of
7.5h. The result of the formulation E was showing weight
variation(0.0519 ± 0.0004), percentage moisture absorption (3.45 ±
1.08), percentage moisture loss (4.8 ± 1.14), water vapour transmission
rate (0.46 ± 0.015g/hr/cm2), thickness (0.056 ± 0.005mm), Folding endurance (1033.67 ±
7.094), tensile strength (0.379 ± 0.006 kg/mm2). In vitro release studies showed zero-order
release from all the patches. The permeation was studies were carried out for 24h showing
release up to 39%. Stability studies are carried out for 7 weeks and indicates that drug remain
stable for that period and primary irritation studies indicated that the transdermal patches are
non irritant.
Keywords: Transdermal patches, Valsartan, HPMC, Hypertension.
[Full Text Article]